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S240 Poster Session Itransplantation (ASCT) at our institute till december, 2007. Pa-
tients’ median age was 52 years (range, 26 to 68 years). High
dose melphalan (200 mg/m2) was used for conditioning. 86
(72.8%) patients had evidence of chemo-sensitive disease prior
to transplant. Response was defined as per EBMT criteria. Fol-
lowing ASCT 80.5% of patients responded; complete (CR) –
46(39%), very good partial response-31(26.3%), and partial re-
sponse-18(15.3%). CR rate was higher for patients with chemo-
sensitive disease; 44 of 86 patients (51.0%) achieved CR com-
pared to 2 of 32 patients (6.2%) with chemo-resistant disease,
p\.001. Response rate to transplant was higher for patients
with serum albumin. 3.3 mg% (p5 0.03), ISS stage- I-II at di-
agnosis (p5 0.001) and Durie-Salmon stage IIIA, p5 0.001. At
a median follow up of 83 months (range, 22 to 155 months),
the median overall (OS) and event-free survival (EFS) is 72
and 29 months, respectively. Estimated OS and EFS at 60
months is 54.2% 6 0.05% (SE) and 32% 6 0.05(SE), respec-
tively. Patients who achieved CR (median not reached yet,
mean 171.91 months +/- 16.2 (SE)) and very good PR (median
84 months) following transplant had a significantly better survival
compared to those with PR (median 38 months,p5 0.0001). Pre-
transplant chemo-sensitive disease (OS: p5 0.006, EFS:
p5 0.007), ISS stage I-II (EFS: p5 0.008) and response to trans-
plant (OS and EFS: p5 0.0001) were important predictors of
survival on multivariate analysis. Six patients (Four disease-free)
were alive at .120 months follow up; all six had pre-transplant
chemo-sensitive disease and had achieved CR after transplant.
Conclusion: Patients with pre-transplant chemo-sensitive disease
and those who achieve complete response following transplant ben-
efit maximum.221
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Purpose: to evaluate the outcome of patients with Hodgkin’s lym-
phoma who underwent autologus hematopoietic stem cell transplan-
tation at the young KHCC bone marrow transplant (BMT)
program.
Patients and Methods: Over the past 6 years, 63 patients with re-
lapsed or refractory Hodgkin’s lymphoma underwent high dose che-
motherapy followed by autologus stem cell transplant. Among the
group there were 54 adults, and 9 children. The median age was
27 years, and 61% of the patients were males.
There were 16 (25.4%) patients in complete remission (CR), 45
(71.4%) with chemotherapy responsive disease and 2 patients (3%)
with stable disease. Prior to conditioning regimen, 35 patients
(56%) received two chemotherapy lines only, and 28 patients
(44%) received more than two lines.
All patients except three received BEAM as pre transplant condi-
tioning.
Results: the main end points of the study are the rate of complete
remission at day 100, overall survival(OS), relapse-free survival
(RFS), correlation of the following variables with OS and RFS: a-dis-
ease status at the time of transplant, b-number of chemotherapy lines
prior to conditioning c-age group.
The median follow up time was 16.0 months (range, 1.25-
44.4months).
The day 100 non-relapse mortality was 4.8%.
The CR at day 100 was 57% (25% before transplant).The median
overall survival for the whole group were 40.6 months, the median
RFS was not reached but currently 63% are still relapse-free.
When we looked at the three variables in correlation with OS,
and RFS in aunivarient analysis, the only statistically significant
correlation was between the number of chemotherapy lines prior
to conditioning and OS, with p value 0.049 in favor of patients
received two lines only. In all other correlations the p value
was not significant.Conclusion: Despite its young age, our program is able to perform
autologous stem cell transplantation for Hodgkin Disease at a reason-
ably acceptable mortality and with an outcome comparable to pub-
lished data.
In our study only the number of chemotherapy lines received be-
fore conditioning had statistically significant correlation with OS.
The disease status at the time of transplant did not have statisti-
cally significant correlation with survival, this is contradicting
some of the published literature, however; this could be mainly
due to the small number of patients, 16 (25%): CR and 45
(71.4%): responsive disease. A complete analysis of data will be pre-
sented at the meeting.PEDIATRIC DISORDERS
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Nijmegen breakage syndrome (NBS) is a rare autosomal recessive
disorder characterized by immunodeficiency, characteristic facial ap-
pearance, chromosomal instability, X-ray hypersensitivity, and pre-
disposition to malignancy. About 40% of patients develop
malignancy mostly of lymphoid origin before age 21. Traditionally
NBS patients have not undergone stem cell transplantation (SCT)
owing to concerns about chromosomal instability and increased tox-
icity. But in the case of resistant or relapsing malignancy SCT may be
the only therapeutic option. We therefore analyzed the transplant
experience in NBS patients in Europe.
A total of six genetically confirmed NBS patients were included.
Median age at diagnosis was 7.6 years (range 1-18) and 14.5 years
(range 2.3-20.3) at transplant. The reason to attempt SCT was resis-
tant or secondary malignancy in four cases. The other two were
transplanted because of severe immunodeficiency or suspected Fan-
coni anemia with immunodeficiency. All had a quantitative and func-
tional T-cell defect and 4/6 had deficient humoral immunity before
transplant. Five patients received reduced intensity regimens with in
vivo T-cell depleting agents. The donors were MSD in 3 patients,
one haploidentical parent and two MUD.
At a median follow up of 3.0 years (range 2.4-9.1) five of six pa-
tients are alive and well. Three patients had no relevant transplant re-
lated complications. One patient died on day +5 from sepsis. He had
received a BMT from a matched sibling after a myeloablative, busul-
fan containing conditioning regimen. Acute GVHD grade I-II oc-
curred in 3/5 patients, mild chronic GVHD in one. Four patients
have complete donor chimerism, one has mixed chimerism, but all
five exhibit restored T-cell immunity.
Although very limited, the experience in these six patients clearly
suggests that SCT in NBS is feasible, can correct the immunodefi-
ciency and effectively treat malignancy. Acute toxicity seems to be
reasonable with reduced intensity conditioning regimens.However,
valid concerns remain about increasing the risk for subsequent ma-
lignancy through cytotoxic agents in these patients.223
POSTGRAFTING IMMUNE SUPPRESSION COMBINEDWITH NONMYELOA-
BLATIVE CONDITIONING FOR TRANSPLANTATION OF HLA-MATCHED
RELATED OR UNRELATED HEMATOPOETIC CELL GRAFTS: PRELIMINARY
RESULTS OF A PHASE II STUDY FOR TREATMENT OF PRIMARY IMMUNO-
DEFICIENCY DISORDERS
Burroughs, L.1,2, Storb, R.1,2, Leisenring, W.1, Torgerson, T.2,
Nemecek, E.3, Frangoul, H.4, Walters, M.5, Scharenberg, A.2,
Rawlings, D.2, Skoda-Smith, S.2, Ochs, H.2,Woolfrey, A.1,2 1FredHutch-
inson Cancer Research Center, Seattle, WA; 2University of Washington
School of Medicine; 3Oregon Health & Sciences University; 4Vanderbilt
University; 5Children’s Hospital, Oakland, CA
